| Primary |
| Langerhans' Cell Histiocytosis |
100.0% |
|
| Langerhans' Cell Histiocytosis |
50.0% |
| Stillbirth |
50.0% |
|
| Secondary |
| Hodgkin's Disease |
42.8% |
| Non-hodgkin's Lymphoma |
8.7% |
| Lung Neoplasm Malignant |
7.3% |
| Breast Cancer |
7.3% |
| Acute Lymphocytic Leukaemia |
5.1% |
| Product Used For Unknown Indication |
4.4% |
| Lymphoma |
3.3% |
| Hodgkin's Lymphoma |
2.6% |
| Hodgkin's Disease Recurrent |
2.4% |
| Hiv Infection |
2.1% |
| Diffuse Large B-cell Lymphoma |
2.1% |
| Choriocarcinoma |
1.8% |
| Ovarian Cancer |
1.8% |
| Foetal Exposure During Pregnancy |
1.6% |
| Invasive Ductal Breast Carcinoma |
1.2% |
| Langerhans' Cell Granulomatosis |
1.2% |
| Metastases To Liver |
1.2% |
| Hodgkin's Disease Stage Iii |
1.1% |
| Testis Cancer |
1.1% |
| Breast Cancer Metastatic |
1.1% |
|
| Haematotoxicity |
17.1% |
| Toxicity To Various Agents |
10.0% |
| Progressive Multifocal Leukoencephalopathy |
7.1% |
| Myelodysplastic Syndrome |
6.5% |
| Acute Lymphocytic Leukaemia |
4.7% |
| Pancytopenia |
4.7% |
| Rash |
4.7% |
| Respiratory Failure |
4.7% |
| Off Label Use |
4.1% |
| Pneumonia |
4.1% |
| Sarcoidosis |
4.1% |
| Hodgkin's Disease Recurrent |
3.5% |
| Non-hodgkin's Lymphoma |
3.5% |
| Vomiting |
3.5% |
| Exposure During Pregnancy |
2.9% |
| Pulmonary Toxicity |
2.9% |
| Second Primary Malignancy |
2.9% |
| Sepsis |
2.9% |
| Thrombocytopenia |
2.9% |
| Tuberculosis |
2.9% |
|
| Concomitant |
| Hodgkin's Disease |
26.8% |
| Chemotherapy |
11.2% |
| Chronic Lymphocytic Leukaemia |
10.1% |
| Metastatic Malignant Melanoma |
6.5% |
| Lymphoma |
6.2% |
| Eczema |
5.7% |
| Non-hodgkin's Lymphoma |
5.2% |
| Transitional Cell Carcinoma |
5.2% |
| Angioimmunoblastic T-cell Lymphoma |
4.2% |
| Drug Use For Unknown Indication |
2.6% |
| Hodgkin's Disease Stage Iii |
2.1% |
| Malignant Melanoma |
2.1% |
| Peripheral T-cell Lymphoma Unspecified |
2.1% |
| Acute Promyelocytic Leukaemia |
1.8% |
| Product Used For Unknown Indication |
1.8% |
| Bladder Cancer |
1.3% |
| Hodgkin's Disease Mixed Cellularity Stage Iii |
1.3% |
| Hypertension |
1.3% |
| Langerhans' Cell Histiocytosis |
1.3% |
| Medulloblastoma |
1.3% |
|
| Hodgkin's Disease |
7.1% |
| Vasogenic Cerebral Oedema |
7.1% |
| Vomiting |
7.1% |
| Weight Decreased |
7.1% |
| Angina Unstable |
5.7% |
| Chronic Lymphocytic Leukaemia |
5.7% |
| Exposure During Pregnancy |
5.7% |
| Pulmonary Fibrosis |
5.7% |
| Rash Papular |
5.7% |
| Scoliosis |
5.7% |
| Disease Progression |
4.3% |
| General Physical Health Deterioration |
4.3% |
| Pulmonary Toxicity |
4.3% |
| Renal Impairment |
4.3% |
| Sepsis |
4.3% |
| Tachycardia |
4.3% |
| Dyspnoea |
2.9% |
| Interstitial Lung Disease |
2.9% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.9% |
| Peripheral T-cell Lymphoma Unspecified |
2.9% |
|
| Interacting |
| Hiv Infection |
39.8% |
| Hodgkin's Disease |
31.3% |
| Drug Use For Unknown Indication |
15.7% |
| Antibiotic Prophylaxis |
7.2% |
| Histoplasmosis |
2.4% |
| Non-hodgkin's Lymphoma |
2.4% |
| Product Used For Unknown Indication |
1.2% |
|
| Drug Interaction |
50.0% |
| Relapsing Fever |
16.7% |
| Infusion Related Reaction |
8.3% |
| Neutropenia |
8.3% |
| Rash |
8.3% |
| Toxicity To Various Agents |
8.3% |
|
